The progress of immunotherapy for glioblastoma

References

• Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S. A population-based description of glioblastoma multiforme in Los Angeles County, 1+74-1999. Cancer 2005; 104(12):2798-806; PMID:16288487; http://dx.doi.org/10.1002/cncr.21539
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005; 352(10):987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10(5):459-66; PMID:19269895; http://dx.doi.org/10.1016/S1470-2045(09)70025-7
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010; 363(5):411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med. 2010; 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Sehgal A, Berger MS. Basic concepts of immunology and neuroimmunology. Neurosurgical FOCUS 2000; 9(6):1-6; http://dx.doi.org/10.3171/foc.2000.9.6.2
   Google Scholar
• Tambuyzer BR, Ponsaerts P, Nouwen EJ. Microglia: gatekeepers of central nervous system immunology. J Leukocyte Biol 2008;85(3):352-70; PMID:19028958; http://dx.doi.org/10.1189/jlb.0608385
   PubMed Web of Science ®Google Scholar
• Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28(2):254-60; PMID:2033653; http://dx.doi.org/10.1002/jnr.490280213
   PubMed Web of Science ®Google Scholar
• Fecci PE. Increased regulatory T-Cell fraction amidst a diminished cd4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66(6):3294-302; PMID:16540683; http://dx.doi.org/10.1158/0008-5472.CAN-05-3773
   PubMed Web of Science ®Google Scholar
• Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010; 2010:1-18; PMID:20953324; http://dx.doi.org/10.1155/2010/689171
   PubMed Web of Science ®Google Scholar
• Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer 2014; 134(10):2437-47; PMID:24614983; http://dx.doi.org/10.1002/ijc.28576
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005; 11(4):1462-6; PMID:15746047; http://dx.doi.org/10.1158/1078-0432.CCR-04-1737
   PubMed Web of Science ®Google Scholar
• Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid 2012; 7:93-103; PMID:23055947
   PubMedGoogle Scholar
• Dixit S. Immunotherapy for high-grade glioma. Future Oncol 2014; 10(6):911-5; PMID:24941977; http://dx.doi.org/10.2217/fon.14.20
   PubMed Web of Science ®Google Scholar
• Xu LW, Chow KKH, Lim M, Li G. Current vaccine trials in glioblastoma: A review. J Immunol Res 2014; 2014:1-10; PMID:24804271; http://dx.doi.org/10.1155/2014/796856
   PubMedGoogle Scholar
• McNulty S, Colaco CA, Blandford LE, Bailey CR, Baschieri S, Todryk S. Heat-shock proteins as dendritic cell-targeting vaccines–getting warmer. Immunology 2013; 139(4):407-15; PMID:23551234; http://dx.doi.org/10.1111/imm.12104
   PubMed Web of Science ®Google Scholar
• Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 2014; 16(2):274-9; PMID:24335700; http://dx.doi.org/10.1093/neuonc/not203
   PubMed Web of Science ®Google Scholar
• Gedeon PC, Riccione KA, Fecci PE, Sampson JH. Antibody-based immunotherapy for malignant glioma. Semin Oncol 2014; 41(4):496-510; PMID:25173142; http://dx.doi.org/10.1053/j.seminoncol.2014.06.004
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24(2):207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28(19):3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
   PubMed Web of Science ®Google Scholar
• Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, et al. Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas. Int J Radiat Oncol 2013; 86(2):343-9; PMID:23462419; http://dx.doi.org/10.1016/j.ijrobp.2012.12.025
   PubMed Web of Science ®Google Scholar
• Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18(7):2039-47; PMID:22271879; http://dx.doi.org/10.1158/1078-0432.CCR-11-1823
   PubMed Web of Science ®Google Scholar
• Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizée G, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 2010; 16(22):5458-68; PMID:20889916; http://dx.doi.org/10.1158/1078-0432.CCR-10-0712
   PubMed Web of Science ®Google Scholar
• Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res 2005; 65(5):2001-8; PMID:15753400; http://dx.doi.org/10.1158/0008-5472.CAN-04-2006
   PubMed Web of Science ®Google Scholar
• Chung DS, Shin HJ, Hong YK. A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res 2014; 2014:326545; PMID:25009822; http://dx.doi.org/10.1155/2014/326545
   PubMed Web of Science ®Google Scholar
• Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol 2012; 90(9):872-80; PMID:22508289; http://dx.doi.org/10.1038/icb.2012.19
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6(224):224r-5r; PMID:24553386; http://dx.doi.org/10.1126/scitranslmed.3008226
   PubMed Web of Science ®Google Scholar
• Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 2014; 20(4):972-84; PMID:24352643; http://dx.doi.org/10.1158/1078-0432.CCR-13-0709
   PubMed Web of Science ®Google Scholar
• Choi BD, Suryadevara CM, Gedeon PC, Herndon JE 2nd, Sanchez-Perez L, Bigner DD, Sampson JH. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 2014; 21(1):189-90; PMID:24054399; http://dx.doi.org/10.1016/j.jocn.2013.03.012
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: adoptive cell transfer immunotherapy. OncoImmunology 2012; 1(3):306-15; PMID:22737606; http://dx.doi.org/10.4161/onci.19549
   PubMed Web of Science ®Google Scholar